Ionis Pharmaceuticals Inc (NAS:IONS)
$ 38.8 -0.28 (-0.72%) Market Cap: 5.66 Bil Enterprise Value: 4.94 Bil PE Ratio: 0 PB Ratio: 19.11 GF Score: 74/100

Ionis Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2021 / 05:20PM GMT
Release Date Price: $36.92 (+0.08%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Ionis with us. And with us from Ionis is Brett Monia, CEO of the company. Brett, thank you for being here this morning -- this afternoon.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

To start, could you walk us through the outlook for the remainder of 2021 in terms of key events and data catalysts for the company?

Brett P. Monia
Ionis Pharmaceuticals, Inc. - Founder, CEO & Director

Sure thing, Salveen, and thanks for the invitation. It's a pleasure to be here today. Yes, quite a number of news coming out of Ionis projected for the second half of the year. Data readouts and as well as new study starts.

Of course, the most exciting data readout that we're really looking forward to is the Phase III readout for tofersen in SOD1-ALS. This is a readout

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot